Teva Sets $57.5 Million Floor For BioXcel Assets, Tying More Value To BXCL501 FDA Timing

BioXcel Therapeutics has filed for Chapter 11 bankruptcy protection and lined up Teva Pharmaceuticals as the stalking horse bidder for substantially all of its assets. The proposed transaction would give BioXcel $57.5 million upfront and up to $67.5 million in milestones, establishing a floor value as the company moves through a court-supervised sale process that could still attract higher offers.

The filing follows a cash crunch that BioXcel recently said left it without enough funds to operate through the end of August. The company secured a $19 million debtor-in-possession financing to maintain operations and fund the Chapter 11 proceedings, and it also filed motions with the court aimed at continuing normal operations, including payment of employee wages and benefits.

The Deal Structure

Teva emerged as the most viable strategic bidder after months of BioXcel efforts to strike a deal, according to the bankruptcy materials cited by Fierce Biotech. BioXcel selected Teva as the stalking horse bidder in part because Teva had already done extensive due diligence on the assets. Teva has submitted a good-faith deposit of $5.7 million.

The economic structure puts unusual weight on regulatory timing. If BXCL501 is approved by the FDA by Nov. 14, BioXcel would receive the full $67.5 million in milestones under the Teva deal. If the agency misses that current PDUFA target but approves the asset by Feb. 27, BioXcel would receive a $55 million milestone. If approval comes after that date, the company would receive a smaller regulatory milestone and become eligible for payments tied to net sales.

BioSpace described the package as a sale of all assets to Teva for up to $125 million, but its story also said the milestone component was an additional $67.5 billion, a figure that conflicts with the rest of its own reporting and with Fierce Biotech’s $67.5 million figure. The more detailed breakdown in the Fierce report supports the milestone structure at up to $67.5 million.

Why BXCL501 Matters Most

The stalking horse agreement centers on BioXcel’s neuroscience assets, with BXCL501 at the core. BXCL501 is an orally dissolving film formulation of dexmedetomidine that is under FDA review for the at-home, acute treatment of agitation associated with bipolar disorders or schizophrenia. BioXcel already markets the drug Igalmi for agitation associated with schizophrenia or bipolar I or II disorder in adults and said it would continue commercial availability and patient support during the bankruptcy process.

BioSpace also noted that BioXcel is investigating Igalmi in agitation associated with Alzheimer’s dementia. Beyond neuroscience, BioXcel has BXCL701, an oral innate immune activator that leads its immuno-oncology pipeline, but the proposed Teva transaction is framed around the neuroscience portfolio rather than the broader pipeline.

For Teva, the bid fits a stated push toward innovative medicines and a broader neuroscience buildout. The company closed its Emalex Biosciences acquisition in June for up to $900 million, and executive vice president of business development Evan Lippman said the BioXcel opportunity strengthens Teva’s neuroscience portfolio while fitting its disciplined approach to innovative assets with clear strategic fit. The signal is that even in bankruptcy, an asset package with a near-term FDA catalyst can still command structured competition if a buyer sees a commercial adjacency worth scaling.